Medicine and Dentistry
Congestive Heart Failure
100%
Ejection Fraction
62%
Maturity Onset Diabetes of the Young
60%
Empagliflozin
55%
Aortic Valve Stenosis
48%
Cardiovascular Disease
41%
Placebo
35%
Aortic Valve Replacement
30%
Diabetes
28%
Pulmonary Embolism
26%
Heart Muscle Ischemia
26%
Prevalence
25%
Hemodynamic
24%
Aortic Stenosis
23%
Diastolic Function
21%
Randomized Clinical Trial
20%
Osteoprotegerin
20%
Arteriosclerosis Obliterans
19%
Randomized Controlled Trial
18%
Heart Ventricle Remodeling
15%
Scintigraphy
15%
Primary Health Care
14%
Hereditary Hemorrhagic Telangiectasia
13%
Vascular Anomaly
13%
Fibulin
13%
Echography
11%
Heart Muscle Perfusion
11%
Diagnostic Imaging
11%
Brain Natriuretic Peptide
11%
Heart Left Ventricle Ejection Fraction
11%
Patient Referral
11%
Amino Terminal Sequence
10%
Heart Failure with Reduced Ejection Fraction
10%
Sodium Glucose Cotransporter 2 Inhibitor
10%
High Output Cardiac Failure
10%
Atrial Fibrillation
9%
Atherosclerosis
9%
Pulmonary Artery Occlusion Pressure
9%
Diagnosis
8%
New York Heart Association Class
8%
Myocardial Disease
8%
Angiotensin Receptor
8%
Chronic Obstructive Pulmonary Disease
8%
Ischemic Heart Disease
8%
Heart Atrium Remodeling
8%
Accelerometer
8%
Left Ventricle
7%
Combination Therapy
7%
Heart Left Ventricle Function
7%
Lung
7%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
80%
Empagliflozin
47%
Placebo
30%
Aortic Valve Stenosis
26%
mRNA Vaccine
20%
SARS Coronavirus
20%
Non Insulin Dependent Diabetes Mellitus
15%
Randomized Clinical Trial
14%
Congenital Blood Vessel Malformation
13%
Rendu Osler Weber Disease
13%
Candesartan
13%
Osteoprotegerin
13%
Prevalence
12%
High Output Heart Failure
10%
Brain Natriuretic Peptide
8%
Immunogenicity
8%
Messenger RNA
8%
Angiotensin Receptor
8%
Diuretic Agent
8%
Heart Failure with Reduced Ejection Fraction
8%
Aortic Stenosis
8%
Sodium Glucose Cotransporter 2 Inhibitor
7%
Enkephalinase Inhibitor
6%
Heart Ventricle Remodeling
6%
Peripheral Occlusive Artery Disease
6%
Trastuzumab
6%
Infection
6%
Chronic Obstructive Lung Disease
6%
Atrial Fibrillation
6%
Deterioration
6%
Isosorbide Dinitrate
6%
Prospective Cohort Study
6%
Breast Cancer
6%
Chemotherapy
6%
Membrane Metalloendopeptidase
6%
Fibulin
6%
Hydralazine
6%
Heart Muscle Ischemia
6%
Metformin
6%
Impaired Glucose Tolerance
6%
Cardiovascular Disease
6%
COVID-19 Vaccine
5%